drugset / Trial / NCT01318499
Nepafenac 0.3% Two Study
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study was to assess the safety and efficacy of Nepafenac Ophthalmic Suspension, 0.3% for the prevention and treatment of inflammation (swelling and redness) and pain in the eye after cataract extraction.
Timeline
- Start
- 2011-03
- Primary completion
- 2011-09
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nepafenac | Other / unclassified | 0.1 % | Other |
| Subject | Nepafenac | Other / unclassified | 0.3 % | Other |